5nance5nance
5nance5nance
HomeScreens
LOGINGET FREE ACCOUNT

Valiant Laboratories Ltd.

•
valiantorganics.comBSE: 543998NSE: VALIANTLAB
Market Cap₹ 583 Cr.
Current Price
High / Low₹ 111 / 50
Stock P/E44.1
Book Value₹ 61
Price to Book1.42
Dividend Yield0.00 %
ROCE-0.4 %
ROE-0.9 %
Face Value₹ 10

Add ratio to table

ABOUT

AI Sector View

AI GENERATED

Healthcare

Buy

This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.

Confidence
50%
View full sector analysis →

PROS

  • Latest quarter profit grew 420.8% YoY, showing strong momentum
  • Strong cash generation - operating cash flow backs reported profits (CFO/PAT 1.83x)
  • Working capital cycle has improved - days down from 367 to 269
  • Company generates healthy free cash flow
  • Company maintains a comfortable, low leverage position

CONS

  • Company is loss-making at the operating / net level
  • Operating cash flow has been negative in recent years
  • Receivables are growing faster than sales - a possible quality concern
  • Interest coverage is weak at -7.3x - earnings barely cover interest
  • Company has a low return on capital employed of 8.5%

* The pros and cons are machine generated based on quantitative rules.

Peer comparison

HealthcareHealthcarePharmaceuticals & Drugs
Part ofNIFTY 50NIFTY 500NIFTY LARGEMIDCAP 250NIFTY 100NIFTY 200
S.No.Name
1.SUNPHARMA1899.0037.67455633.710.842901.2326.5315299.8810.9819.1128.81
2.DIVISLAB9100.0082.59241576.410.33902.0065.503080.0027.8021.5140.75
3.TORNTPHARM4850.0084.58184478.410.78566.003.284921.0057.3219.2733.81
4.CIPLA1385.0033.19111888.390.94785.55-39.187119.284.1316.0016.73
5.ZYDUSLIFE1121.0024.78111820.180.09990.20-34.908017.0023.9721.3924.54
6.LAURUSLABS1840.0090.9399417.450.11362.07123.942026.3129.1018.2031.50
7.LUPIN2111.0017.4696528.820.851416.9816.018276.8934.2828.8629.59
8.DRREDDY1154.0029.8996322.060.69435.60-69.108099.80-5.2113.7510.63
9.MANKIND2328.5547.0996179.610.04574.0929.124030.5912.8913.2426.30
10.AUROPHARMA1653.3025.6295127.230.241032.0325.229150.3517.4412.7620.54
11.GLENMARK2427.0038.1068495.930.10482.83927.884018.4831.3520.3520.03
12.VALIANTLAB107.2736.40582.610.0021.101058.87115.28146.23-0.4025.38
Detailed Comparison with:

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
51604131192135585146556573
48614735212835544946546162
Operating Profit4-1-6-5-2-714200412
OPM %7.43%-2.32%-15.55%-14.81%-12.66%-31.38%1.76%6.63%4.63%0.13%0.46%6.89%16.17%
2322221111111
Interest0000000000000
Depreciation0000011111111
Profit before Tax61-5-3-1-514200513
Tax %26.12%25.47%30.50%52.16%-29.87%-12.41%-122.22%17.60%25.71%34.62%72.73%25.32%25.53%
Net Profit41-4-1-1-62320049
1.310.24-0.81-0.32-0.23-1.390.370.740.420.030.010.651.75

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2022Mar 2023Mar 2024Mar 2025TTM
292334182133239
249299190138223
Operating Profit4235-8-517
OPM %14.52%10.50%-4.62%-3.52%6.97%
251053
Interest00000
Depreciation22222
Profit before Tax4238-1-118
Tax %34.07%23.96%145.22%-48.51%25.89%
Net Profit27290-213
EPS9.528.910.08-0.49—
Dividend Payout %0.00%0.00%0.00%0.00%—

COMPOUNDED SALES GROWTH

10 Years:
—
5 Years:
—
3 Years:
-23%

COMPOUNDED PROFIT GROWTH

10 Years:
—
5 Years:
—
3 Years:
—

STOCK PRICE CAGR

10 Years:
—
5 Years:
—
3 Years:
—
1 Year:
23%

RETURN ON EQUITY

10 Years:
—
5 Years:
—
3 Years:
11%
Last Year:
-1%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Corporate actions

No bonus data found

Mar 2022Mar 2023Mar 2024Mar 2025
Equity Capital16334343
5568193191
62616161
Trade Payables46472519
2423
Total Liabilities182213325317
22303230
Capital Work in Progress1000
034119165
1613104
004672
Cash & Bank2009727
1221352219
Total Assets182213325317

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2022Mar 2023Mar 2024Mar 2025
173249-22
Cash from Investing-12-21-18325
Cash from Financing6-2136-1
-4023

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2022Mar 2023Mar 2024Mar 2025
PER SHARE
EPS (₹)16.898.910.08-0.49
Book Value (₹)43.8930.8654.5253.94
Dividend per Share (₹)0.000.000.000.00
Cash EPS (₹)8.558.710.49-0.03
PROFITABILITY
Operating Margin %15.18%11.97%-4.62%-3.52%
Net Margin %9.43%8.68%0.19%-1.61%
ROE %38.48%33.73%0.20%-0.91%
ROCE %31.62%26.29%-0.30%-0.43%
15.12%14.70%0.13%-0.67%
EFFICIENCY
Debtor Days139109135161
Inventory Days20162319
Payable Days72627969
866379111
FINANCIAL HEALTH
Debt to Equity (x)0.85x0.59x0.25x0.25x
Interest Coverage (x)572.29x151.32x-8.67x-7.26x
3.17x3.60x7.94x5.69x
GROWTH
Revenue Growth %0.00%14.54%-45.48%-26.75%
Operating Profit Growth %0.00%-9.74%-96.81%-40.94%
Net Profit Growth %0.00%5.46%-98.83%-731.85%
0.00%0.00%-99.12%-731.85%
VALUATION
P/E (x)0.00x0.00x1725.47x0.00x
P/B (x)0.00x0.00x2.67x1.42x
Dividend Yield %0.00%0.00%0.00%0.00%
0.00x0.00x467.50x486.26x

Shareholding Pattern

Numbers in percentages

Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
74.9474.9474.9474.9474.9474.9474.9474.9474.94
1.890.000.000.640.630.020.010.200.00
DIIs0.000.000.000.000.000.000.000.000.00
Government0.000.000.000.000.000.000.000.000.00
23.1725.0625.0624.4224.4325.0425.0524.8625.06

Documents

Corporate disclosures, annual reports, credit ratings, and concall transcripts

2026-09-04
Copy of Newspaper Publication

2026-09-04 - Valiant Laboratories Limited has informed the Exchange regarding Dispatch of Annual Report for FY 2025-26 and Notice of 5th Annual General Meeting to the members of the Company.

2026-09-03
Credit Rating

2026-09-03 - Valiant Laboratories Limited has informed the Exchange about Credit Rating

2026-09-03
General Updates

2026-09-03 - Valiant Laboratories Limited has informed the Exchange 'Letter to shareholders under Regulation 36(1)(b) of SEBI (LODR) Regulations 2015'.

2026-09-03
Shareholders meeting

2026-09-03 - Valiant Laboratories Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 28, 2026 and the Annual Report for the FY 2025-26

2026-08-31
Copy of Newspaper Publication

2026-08-31 - Valiant Laboratories Limited has informed the Exchange about Copy of Newspaper Publication w.r.t. 5th AGM of the Company

2026-08-12
Copy of Newspaper Publication

2026-08-12 - Valiant Laboratories Limited has informed the Exchange about Copy of Newspaper Publication

2026-08-10
Monitoring Agency Report

2026-08-10 - Monitoring Agency Report for quarter ended June 30, 2026

2026-08-10
Address Change

2026-08-10 - Valiant Laboratories Limited has informed the Exchange regarding change in Corporate Office of the company.

2026-08-10
Address Change

2026-08-10 - Valiant Laboratories Limited has informed the Exchange regarding change in Registered Office of the company.

News

Recent coverage and analyst commentary for VALIANTLAB

Loading news…

🤖

AI Stock Analyst

Valiant Laboratories Ltd.

🔒

Sign in to Chat with AI

Log in with your 5nance account to ask institutional questions about performance, financials, and outlook.

✨ Sign In to Chat

Free 5nance Account

5nance5nance

Stock analysis and screening tool

5nanceAI © 2020-2026

Made with ❤️ in India.

Data provided by Accord Fintech

Terms & Privacy.

Product

PremiumWhat's new?Learn

Team

About usSupport

Theme

5nance5nance

Product

PremiumWhat's new?Learn

Team

About usSupport

Theme


5nanceAI © 2020-2026

Data provided by Accord Fintech

Made with ❤️ in India.

HomeScreens
Login